Navigation Links
Hard To Treat Diseases (HTDS.PK) IP Rights Pink Sheets Filings
Date:8/26/2009

SHENZHEN, China, Aug. 26 /PRNewswire-FirstCall/ - Hard to Treat Diseases (the "Company") (HTDS.PK) www.htdsmedical.com provides access to U.S. Patent and Trademark Office.("USPTO") documents relating to intellectual property ("IP") ownership rights of the Company.

HTDS management has duly notified the OTCBB company utilizing the IP rights of the Company and is providing its shareholders with certain other "Supplementary" filings made yesterday with Pink Sheets. The information can be accessed at http://www.pinksheets.com/pink/quote/quote.jsp?symbol=htds

The supplementary filings made on Pink Sheets by HTDS include the actual copies of the USPTO recording documents, the letter to the OTCBB Company utilizing HTDS rights and proof of FedEx delivery of the same.

These documents are self explanatory.

HTDS management is of the opinion that this information is material, and both issuers need to disclose its potential effect to its shareholders and investors. The OTCBB company is in default in their filings with the SEC. and has received an "e" on its symbol as a late filing issuer.

HTDS ownership rights for the five patents can be accessed at the following five USPTO websites:

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=5223543 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=6743828 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7241858 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7321003 pub= asnr= asnri= asne= asnei= asns=

http://assignments.uspto.gov/assignments/q?db=pat qt=pat reel= frame= pat=7476696 pub= asnr= asnri= asne= asnei= asns=

HTDS management will continue to monitor the situation and intends to vigorously escalate its claim to protect its interests. The Company is not ruling out any available options at this point regarding the IP rights that may have a positive significant impact on the entire value of HTDS.

Further updates to follow.

Safe Harbor Statement:

Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, please contact corporate@htdsmedical.com, www.htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The Berry Truth: Cystex Know Your Bladder Better Video Explains Why Cranberries Are Great for UTI Prevention, But Not for Treatment
2. Experimental Treatment Could Fight Muscular Dystrophy
3. Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer
4. Surgical treatment a rare complication of duodenal diverticulum
5. Introducing anuleaf AD, a New FDA-Approved Hemorrhoid Treatment
6. Treating Prostate Cancer: Old School vs. New School
7. Valeant Pharmaceuticals Announces Preliminary Results From Its Phase IIa Retigabine Study for the Treatment of Postherpetic Neuralgia (PHN)
8. EndyMed Medical Receives FDA Clearance for Painless, Non-invasive Anti-Wrinkle Treatment System
9. New treatments offer better survival and fresh challenges in colorectal cancer
10. Study finds low risk in treating previously coiled aneurysm
11. Night home hemodialysis shown to be as good as transplant in treating kidney failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known for myriad ... a show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a ... plummeted in large part due to early detection. Like any other disease, treatments have ...
(Date:12/4/2016)... CA (PRWEB) , ... December 04, 2016 , ... ... without undergoing major cosmetic surgery can now take advantage of a cosmetic procedure ... advanced skin rejuvenation treatment that reduces the appearance of age spots, fine ...
(Date:12/2/2016)... ... 02, 2016 , ... Lori G. Cohen and Sara K. ... at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference , ... of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 ... are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This ... area students and operating support to UNCF-member institutions, including Miles College, Oakwood University, ...
(Date:12/2/2016)... , ... December 02, 2016 , ... The annual time ... Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are ... or prescription drug plan (Part D) need to make changes during this period order ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Research and Markets has announced the ... their offering. ... R&D Drug Pipeline Database: 1-Year ... Drug Pipeline Database provides 24/7 online access to information about more ... and on investigational drug candidates in research & development. ...
(Date:12/2/2016)... , December 2, 2016 bioLytical Laboratories, un líder mundial ... el INSTI HIV Self Test , a los miembros de la Kenya ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) bioLytical fue ...
(Date:12/2/2016)...  LifeVac, the revolutionary device that has successfully rescued ... Training and Support Services (ERTSS) training programs. ... part of the ERTSS mission to save lives," said ... "Having an established network of expert trainers demonstrating how ... our efforts to spread LifeVac,s message that choking deaths ...
Breaking Medicine Technology: